ACOG
Alpha Cognition Inc. Common StockACOG
ACOG
About: Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Employees: 57
0
Funds holding %
of 7,345 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1.3% more ownership
Funds ownership: 38.27% [Q4 2024] → 39.57% (+1.3%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
4% less funds holding
Funds holding: 23 [Q4 2024] → 22 (-1) [Q1 2025]
7% less capital invested
Capital invested by funds: $34.9M [Q4 2024] → $32.4M (-$2.46M) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$20
156%
upside
Avg. target
$20
156%
upside
High target
$20
156%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 156%upside $20 | Buy Reiterated | 16 May 2025 |
Financial journalist opinion
Based on 5 articles about ACOG published over the past 30 days
Negative
Zacks Investment Research
15 hours ago
Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.25 per share a year ago.
Neutral
Seeking Alpha
15 hours ago
Alpha Cognition Inc. (ACOG) Q2 2025 Earnings Call Transcript
Alpha Cognition Inc. (NASDAQ:ACOG ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Henry Du - VP of Finance & Accounting and Interim CFO Lauren D'Angelo - Chief Operating Officer Michael E. McFadden - CEO & Director Conference Call Participants David Joseph Storms - Stonegate Capital Partners, Inc., Research Division Raghuram Selvaraju - H.C.
Neutral
Business Wire
1 day ago
Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”) today announced its financial results for the second quarter ended June 30, 2025. “The initial ZUNVEYL launch has been met with strong interest from both healthcare providers and patients. Early adoption in nursing homes and by geriatric specialists has created a solid foundation for future growth,” said Michael McFadden, Chief Executive Officer of Alpha Cogn.
Neutral
Business Wire
1 week ago
Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-.
Neutral
Business Wire
2 weeks ago
Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer's Disease
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced China Medical System Holdings Limited (CMS) New Drug Application (NDA) for ZUNVEYL has been accepted by the National Medical Products Administration of China (NMPA) for review for the treatment of mild-to-moderate Alzheimer's dementia. “We are pl.
Neutral
Business Wire
1 month ago
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will share the following poster presentations: Bioequivalence of ZUNVEYL,.
Positive
Zacks Investment Research
1 month ago
What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock
Alpha Cognition Inc. (ACOG) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Business Wire
1 month ago
Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The data provides additional evidence of benefits of ALPHA-1062, in the treatment of mTBI resulting from repetitive blast.
Positive
Zacks Investment Research
1 month ago
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
Here is how Alpha Cognition Inc. (ACOG) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
1 month ago
Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross?
Alpha Cognition Inc. (ACOG) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACOG's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Charts implemented using Lightweight Charts™